<?xml version="1.0" encoding="UTF-8" standalone="no"?><?xml-stylesheet type="text/css" href="uslm.css"?><pLaw xmlns="http://schemas.gpo.gov/xml/uslm" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" xsi:schemaLocation="http://schemas.gpo.gov/xml/uslm https://www.govinfo.gov/schemas/xml/uslm/uslm-2.0.17.xsd">

<?I97 ??>
<?I50 PUBLIC LAW 119–32—AUG. 14, 2025?>


<?I97 139 STAT. ?>
<?I98 139 STAT. ?>
<?I99 139 STAT. ?>
<?I50 PUBLIC LAW 119–32—AUG. 14, 2025?>
<?I51 PUBLIC LAW 119–32—AUG. 14, 2025?>
<?I52 PUBLIC LAW 119–32—AUG. 14, 2025?>


<!--Disclaimer: Legislative measures that include compacts or other non-standard data structures will require additional modeling and may contain inconsistencies in the converted USLM XML.-->
<meta><dc:title>Public Law 119–32: To provide for a study by the National Academies of Sciences, Engineering, and Medicine on the prevalence and mortality of cancer among individuals who served as active duty aircrew in the Armed Forces, and for other purposes.</dc:title>
<dc:type>Public Law</dc:type><docNumber>32</docNumber>
<citableAs>Public Law 119–32</citableAs><citableAs>139 Stat. 480</citableAs>
<approvedDate>2025-08-14</approvedDate>
<dc:date>2025-08-14</dc:date>
<dc:publisher>United States Government Publishing Office</dc:publisher><dc:creator>National Archives and Records Administration</dc:creator><dc:creator>Office of the Federal Register</dc:creator><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<processedBy>GPO Locator to USLM Converter 4.12.3;Stage2.20240826</processedBy><processedDate>2025-08-22</processedDate>
<congress>119</congress><publicPrivate>public</publicPrivate>
</meta>
<preface><page display="no">?479</page><note role="coverPage"><centerRunningHead>PUBLIC LAW 119–32—AUG. 14, 2025</centerRunningHead>
<coverTitle>ACES ACT OF 2025</coverTitle>
</note>
<page identifier="/us/stat/139/480">139 STAT. 480</page>
<dc:type>Public Law</dc:type><docNumber>119–32</docNumber>
<congress value="119">119th Congress</congress>
</preface>
<main>
<longTitle>
<docTitle class="centered fontsize12" style="-uslm-lc:I658005">An Act</docTitle>
<officialTitle class="indentUp0 firstIndent1 fontsize8" style="-uslm-lc:I658011">To provide for a study by the National Academies of Sciences, Engineering, and Medicine on the prevalence and mortality of cancer among individuals who served as active duty aircrew in the Armed Forces, and for other purposes.<sidenote><p class="centered fontsize8" id="x792b999c-7f5a-11f0-b788-db5648f39697" style="-uslm-lc:I658076"><approvedDate date="2025-08-14">Aug. 14, 2025</approvedDate></p><p class="centered fontsize8" id="x792b999d-7f5a-11f0-b788-db5648f39697" style="-uslm-lc:I658076">[<ref href="/us/bill/119/s/201">S. 201</ref>]<?GPOvSpace 08?></p></sidenote></officialTitle>
</longTitle>
<enactingFormula style="-uslm-lc:I658120"><i>  Be it enacted by the Senate and House of Representa­tives of the United States of America in Congress assembled,</i></enactingFormula><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x792b999e-7f5a-11f0-b788-db5648f39697" style="-uslm-lc:I658180">ACES Act of 2025.</p></sidenote>
<section id="d292e98" identifier="/us/pl/119/32/s1" style="-uslm-lc:I658146"><num class="bold" value="1">SECTION 1. </num><heading>SHORT TITLE.</heading><content style="-uslm-lc:I658120">  This Act may be cited as the “<shortTitle role="act">ACES Act of 2025</shortTitle>”.</content></section>
<section id="d292e108" identifier="/us/pl/119/32/s2" style="-uslm-lc:I658141"><num class="fontsize12" value="2">SEC. 2. </num><heading>NATIONAL ACADEMIES STUDY ON PREVALENCE AND MORTALITY OF CANCER AMONG INDIVIDUALS WHO SERVED AS ACTIVE DUTY AIRCREW IN THE ARMED FORCES.</heading><subsection class="firstIndent0 fontsize10" id="y792e0a9f-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/a" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10 smallCaps">Agreement<inline class="noSmallCaps">.—</inline></heading><paragraph class="fontsize10" id="y792e0aa0-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/a/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><heading class="fontsize10"><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x792e0aa1-7f5a-11f0-b788-db5648f39697" style="-uslm-lc:I658180">Deadline.</p></sidenote><inline class="smallCaps">In general</inline>.—</heading><content>Not later than 30 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall seek to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (in this section referred to as the “National Academies”), under which the National Academies shall conduct a study on the prevalence and mortality of cancers among covered individuals.</content></paragraph><paragraph class="fontsize10" id="y792e0aa2-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/a/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><heading class="fontsize10 smallCaps">Deadline<inline class="noSmallCaps">.—</inline></heading><subparagraph class="fontsize10" id="y792e0aa3-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/a/2/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><heading class="fontsize10 smallCaps">Date<inline class="noSmallCaps">.—</inline></heading><content>The Secretary shall finalize the agreement under paragraph (1) by not later than 60 days after the date on which the Secretary enters negotiations with the National Academies with respect to such agreement.</content></subparagraph><subparagraph class="fontsize10" id="y792e0aa4-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/a/2/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><heading class="fontsize10 smallCaps">Report; briefings<inline class="noSmallCaps">.—</inline></heading><chapeau>If the Secretary fails to satisfy the requirement under subparagraph (A), the Secretary shall—</chapeau><clause class="fontsize10" id="y792e0aa5-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/a/2/B/i" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><chapeau>submit to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a report that includes—</chapeau><subclause class="fontsize10" id="y792e0aa6-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/a/2/B/i/I" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">(I) </num><content>an explanation of the reasons the Secretary failed to satisfy such requirement; and</content></subclause><subclause class="fontsize10" id="y792e0aa7-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/a/2/B/i/II" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="II">(II) </num><content>an estimate of the date on which the Secretary will finalize the agreement under paragraph (1); and</content></subclause></clause><clause class="fontsize10" id="y792e0aa8-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/a/2/B/ii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>not less frequently than once every 60 days after the date on which the Secretary failed to satisfy such requirement, provide to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a briefing on the progress of the Secretary toward finalizing such agreement.<page identifier="/us/stat/139/481">139 STAT. 481</page></content></clause></subparagraph></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y792e31b9-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><heading class="fontsize10 smallCaps">Study<inline class="noSmallCaps">.—</inline></heading><chapeau>The study required under subsection (a) shall—</chapeau><paragraph class="fontsize10" id="y792e31ba-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>identify exposures associated with military occupations of covered individuals, including relating to chemicals, compounds, agents, and other phenomena;</content></paragraph><paragraph class="fontsize10" id="y792e31bb-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><chapeau>review the literature to determine associations between exposures referred to in paragraph (1) and the incidence or prevalence of overall cancer morbidity, overall cancer mortality, and increased incidence or prevalence of—</chapeau><subparagraph class="fontsize10" id="y792e31bc-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>brain cancer;</content></subparagraph><subparagraph class="fontsize10" id="y792e31bd-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><content>colon and rectal cancers;</content></subparagraph><subparagraph class="fontsize10" id="y792e31be-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/C" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">(C) </num><content>kidney cancer;</content></subparagraph><subparagraph class="fontsize10" id="y792e31bf-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/D" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="D">(D) </num><content>lung cancer;</content></subparagraph><subparagraph class="fontsize10" id="y792e31c0-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/E" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="E">(E) </num><content>melanoma skin cancer;</content></subparagraph><subparagraph class="fontsize10" id="y792e31c1-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/F" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="F">(F) </num><content>non-Hodgkin lymphoma;</content></subparagraph><subparagraph class="fontsize10" id="y792e31c2-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/G" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="G">(G) </num><content>pancreatic cancer;</content></subparagraph><subparagraph class="fontsize10" id="y792e31c3-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/H" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="H">(H) </num><content>prostate cancer;</content></subparagraph><subparagraph class="fontsize10" id="y792e31c4-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/I" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">(I) </num><content>testicular cancer;</content></subparagraph><subparagraph class="fontsize10" id="y792e31c5-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/J" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="J">(J) </num><content>thyroid cancer;</content></subparagraph><subparagraph class="fontsize10" id="y792e31c6-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/K" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="K">(K) </num><content>urinary bladder cancer; and</content></subparagraph><subparagraph class="fontsize10" id="y792e31c7-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/2/L" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="L">(L) </num><content>other cancers as determined appropriate by the Secretary of Veterans Affairs, in consultation with the National Academies; and</content></subparagraph></paragraph><paragraph class="fontsize10" id="y792e58d8-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/3" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><chapeau>determine, to the extent possible, the prevalence of and mortality from the cancers specified in paragraph (2) among covered individuals by using available sources of data, which may include—</chapeau><subparagraph class="fontsize10" id="y792e58d9-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/3/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>health care and other administrative databases of the Department of Veterans Affairs, the Department of Defense, and the individual Services, respectively;</content></subparagraph><subparagraph class="fontsize10" id="y792e58da-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/3/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><content>the national death index maintained by the National Center for Health Statistics of the Centers for Disease Control and Prevention; and</content></subparagraph><subparagraph class="fontsize10" id="y792e58db-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/b/3/C" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">(C) </num><content>the study conducted under section 750 of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (<ref href="/us/pl/116/283">Public Law 116–283</ref>; <ref href="/us/stat/134/3716">134 Stat. 3716</ref>).</content></subparagraph></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y792e58dc-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/c" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="c">(c) </num><heading class="fontsize10 smallCaps">Report<inline class="noSmallCaps">.—</inline></heading><content>At the conclusion of the study required under subsection (a), the National Academies shall submit to the Secretary, the Committee on Veterans’ Affairs of the Senate, and the Committee on Veterans’ Affairs of the House of Representatives a report containing the results of the study described in subsection (b).</content></subsection><subsection class="firstIndent0 fontsize10" id="y792e58dd-7f5a-11f0-b788-db5648f39697" identifier="/us/pl/119/32/s2/d" role="definitions" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="d">(d) </num><heading class="fontsize10 smallCaps">Covered Individual Defined<inline class="noSmallCaps">.—</inline></heading><content>In this section, the term “<term>covered individual</term>” means an individual who served on active duty in the Army, Navy, Air Force, or Marine Corps as an aircrew member of a fixed-wing aircraft, including as a pilot, navigator, <page identifier="/us/stat/139/482">139 STAT. 482</page>
weapons systems operator, aircraft system operator, or any other crew member who regularly flew in a fixed-wing aircraft.</content></subsection></section>
<action>
<actionDescription style="-uslm-lc:I658030">Approved</actionDescription> <date date="2025-08-14">August 14, 2025</date>.</action>
</main>
<legislativeHistory>
<heading style="-uslm-lc:I658031"><inline class="underline">LEGISLATIVE HISTORY</inline>—<ref href="/us/bill/119/s/201">S. 201</ref> (<ref href="/us/bill/119/hr/530">H.R. 530</ref>):</heading>
<note>
<heading style="-uslm-lc:I658032">CONGRESSIONAL RECORD, Vol. 171 (2025):</heading>
<p class="indentUp4 firstIndent-1" id="x792e58de-7f5a-11f0-b788-db5648f39697" style="-uslm-lc:I658035">June 3, considered and passed Senate.</p><p class="indentUp4 firstIndent-1" id="x792e58df-7f5a-11f0-b788-db5648f39697" style="-uslm-lc:I658035">July 21, considered and passed House.</p></note>
</legislativeHistory>
<endMarker>○</endMarker>
</pLaw>